FDC346.40

FDC Limited

· Pharma & Health
₹ CrorePeersIOLCPMOREPENLABINNOVACAPORCHPHARMASENORESGUJTHEMRPGLIFESANOFIMcap ₹5,640 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation39.953.759.2
+ Finance Costs0.04.55.0
+ Dividend Income0.00.0-0.0
+ Fair Value (Gains) / Losses-64.7-24.3-11.8
+ Unrealised FX (Gain) / Loss0.1-0.2-1.4
+ Other Non-cash Items0.0-0.50.4
+ Other — Cash Effects are Investing / Financing0.0-10.3-31.8
+ Other Reconciling Items-0.0-0.2-0.4
Changes in Working Capital
+ Inventories-58.017.022.2
+ Trade Receivables — Current5.07.8-42.1
+ Other Financial Assets — Current-3.81.6-1.0
+ Other Current Assets17.714.3-34.6
+ Trade Payables — Current10.741.12.5
+ Provisions — Current8.06.1-0.8
Cash from Operating Activities
Profit Before Tax (per I/S)396.2357.2374.6389.5
+ Total Adjustments (incl. Working Capital)-45.1110.5-34.6
Cash from Operations (pre-tax)351.1467.8340.0
+ Interest Received — Operating-30.4-47.4-52.4
+ Interest Paid — Operating-4.00.00.0
+ Dividends Received — Operating-0.1-0.00.0
+ Income Taxes Paid103.9102.887.2
Cash from Operating Activities220.8317.6200.5
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)93.496.7186.6
+ Disp of Fixed Assets23.95.826.5
+ Acq of Other Long-term Assets506.5537.3506.9
+ Disp of Other Long-term Assets530.8381.4507.8
+ Dividends Received — Investing0.10.00.0
+ Interest Received — Investing28.047.449.2
+ Other Inflows / (Outflows) — Investing0.00.0-0.0
Cash from Investing Activities-17.1-199.5-109.9
Cash from Financing Activities
+ Buyback / Redemption of Own Shares191.80.00.0
+ Repayment of Borrowings0.10.00.1
+ Payment of Lease Liabilities9.610.211.4
+ Interest Paid0.50.00.0
+ Dividends Paid0.181.181.0
+ Other Inflows / (Outflows) — Financing0.0-0.8-0.8
Cash from Financing Activities-202.2-92.1-93.3
Net Changes in Cash (pre-FX)1.525.9-2.8
+ Effect of FX Rate Changes on Cash0.00.10.0
Net Changes in Cash1.526.1-2.8
Closing Cash25.4
Reference Items
EBITDA338.5324.8346.1335.5
EBITDA Margin %17.4215.4115.9415.32
Free Cash Flow (CFO − Capex)127.4220.813.913.9
Free Cash Flow to Equity220.713.8
Free Cash Flow per Basic Share7.8213.560.850.85
Price to Free Cash Flow406.05
Cash Flow to Net Income0.721.190.71
Cash Paid for Taxes103.9102.887.2
Cash Paid for Interest0.50.00.0
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.